2025 San Antonio Breast Cancer Symposium (SABCS 2025)
San Antonio, Texas, US 09 December 2025 - 12 December 2025
Use of sacituzumab govitecan safe, efficacious in pretreated mBC
A recent China study has provided further evidence on the real-world efficacy and safety of sacituzumab govitecan (SG) in HR+/HER2- and triple-negative breast cancer (TNBC) patients who have received at least three lines of prior therapy.
Use of sacituzumab govitecan safe, efficacious in pretreated mBC
20 Jan 2026
Cruciferous veggies protective against breast cancer?
An analysis using data from two large prospective studies demonstrates the protective effect of cruciferous vegetable consumption against breast cancer.
Cruciferous veggies protective against breast cancer?
20 Jan 2026
Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer
A real-world study of the antibody-drug conjugate (ADC) sacituzumab govitecan in patients with HR+/ HER2- metastatic breast cancer (mBC) or metastatic triple-negative breast cancer (mTNBC) shows consistent survival outcomes as those seen in clinical trials.
Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer
19 Jan 2026
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).